Economics of SLIT

George F. Kroker, MD

©2007 Allergychoices, Inc. All Rights Reserved.

Economics of SLIT

©2007 Allergychoices, Inc. All Rights Reserved.

Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhiniconjunctivitis—A Northern European perspective

Bachert C, Vestenbaek U, Christensen J, et alClinical & Experimental Allergy 37: 772-779, 2007

Economics of SLIT: GRAZAX Study

©2007 Allergychoices, Inc. All Rights Reserved.

Patients with allergic rhinoconjunctivitis randomized to a grass allergen tablet arm (316 pts) and to a placebo arm (318 pts)

Grass allergen arm: 1 tab/day for 3 consecutive yrs+ medication; f/u in 9 years

Placebo arm: medication only; f/u in 9 years

Economics of SLIT: GRAZAX Study

©2007 Allergychoices, Inc. All Rights Reserved.

Patients on GRAZAX used significantly less symptomatic medication & missed significantly fewer hours from work than the placebo group

“It can be concluded that the grass allergen tablet is cost-effective for the treatment of grass pollen induced rhinoconjunctivitis in Northern European countries…at an annual cost below 2200 Euro (equivalent to a tablet price of 6.03 Euro)”

The current price of GRAZAX is 2.95 Euro in Germany

Economics of SLIT

©2007 Allergychoices, Inc. All Rights Reserved.

Economic evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-induced respiratory allergy: The Sublingual Immunotherapy Pollen Allergy Italy (SPAI) study

Berto P, Passalacqua G, Crimi N, et alAnnals of Allergy, Asthma, Immunology 97: 615-621, 2006

Economics of SLIT: SPAI Study

©2007 Allergychoices, Inc. All Rights Reserved.

Study compared costs, clinical outcomes, and cost-effectiveness of 2 strategies in the management of allergic rhinitis and asthma: SLIT with pharmacotherapy, and pharmacotherapy (no SLIT)

27 physicians from 25 allergy centers performed retrospective analysis from clinical records of approximately 100 young adults with allergic rhinitis with or without asthma

Data collected on 2230 patients—60.2% had rhinitis only and 39.8% had rhinitis with asthma

Economics of SLIT: SPAI Study

SLIT NO SLIT

Symptom Improvement 631 per 1000 pts 232 per 1000 pts

Asthma prevention 518 per 1000 pts 289 per 1000 pts

Cost per pt thru NHS Lower after 4.5 yrs Higher after 4.5 yrs

Societal cost per pt Lower for all 6 yrs Higher for all 6 years

Direct cost per pt at >6 yrs 2400 Euro 3026 Euro

Indirect cost per pt at >6 yrs 1013 Euro 3400 Euro

©2007 Allergychoices, Inc. All Rights Reserved.

Economics of SLIT: SPAI Study

©2007 Allergychoices, Inc. All Rights Reserved.

Conclusions:“SLIT improved the symptoms of 399 of 1000 patients and prevented asthma in 229 of 1000 patients compared with drugs alone…SLIT is less expensive and more effective than pharmacotherapy alone”